Recite me link

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?
a. Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent
b. Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
c. Abemaciclib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Carboplatin or Cisplatin as a single agent
h. Eribulin as a single agent or in combination
i. Everolimus + Exemestane
j. Fluorouracil
k. Fulvestrant as a single agent
l. Goserelin
m. Lapatinib
n. Neratinib
o. Olaparib
p. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
q. Palbociclib + Fulvestrant
r. Pertuzumab + Trastuzumab + Docetaxel
s. Platinum (e.g. carboplatin or cisplatin) as a single agent
t. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
u. Ribociclib + Fulvestrant
v. Talazoparib
w. Tamoxifen
x. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
y. Transtuzumab as a single agent
z. Trastuzumab emtansine
aa. Transtuzumab deruxtecan
bb. Any other active systemic anti-cancer therapy

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?

Download response Breast cancer. 251021.docx